Claims for Patent: 10,532,098
✉ Email this page to a colleague
Summary for Patent: 10,532,098
Title: | Stabilized aqueous antibody compositions |
Abstract: | The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range n=2-12. |
Inventor(s): | Jezek; Jan (Saffron Walden, GB), Casy; Guy (Saffron Walden, GB), Derham; Barry Kingston (Saffron Walden, GB), Royle; Nikki (Saffron Walden, GB) |
Assignee: | Arecor Limited (Cambridge, GB) |
Application Number: | 14/375,257 |
Patent Claims: | 1. An aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine, wherein (a) the aqueous solution
is substantially free of a buffer with a pKa within 1 unit of the pH of the solution, (b) the antibody is (i) trastuzumab, (ii) rituximab, (iii) infliximab, (iv) a fusion protein comprising an active protein domain fused to one or more immunoglobulin Fc
fragments, or (v) certolizumab pegol; and (c) the number of repeating units of ethyleneimine (n) in the oligomer is in the range consisting of 2 to 12.
2. The aqueous solution of claim 1, wherein the number of repeating units of ethyleneimine (n) is 3. 3. The aqueous solution of claim 1, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range consisting of n=3 to 5. 4. The aqueous solution of claim 1, wherein the oligomer of ethyleneimine is derivatised with one or more PEG or mPEG groups. 5. The aqueous solution of claim 4, wherein the oligomer of ethyleneimine is derivatised via an optional bridging group, wherein said bridging group is selected from the group consisting of carbonyl, amide, carbamate, urea and alkylene. 6. The aqueous solution of claim 1, wherein the oligomer of ethyleneimine is selected from the group consisting of diethylenetriamine, triethylenetetramine, tetraethylenepentamine and pentaethylenehexamine. 7. The aqueous solution of claim 1, wherein 80 to 100% of the basic nitrogen centres of the oligomer of ethyleneimine are protonated. 8. The aqueous solution or method of claim 1, wherein the oligomer of ethyleneimine is present at a concentration of about 0.01 mg/mL to about 10 mg/mL. 9. The aqueous solution of claim 1, wherein the antibody protein is a therapeutic agent. 10. The aqueous solution of claim 1, wherein the antibody protein is trastuzumab, rituximab or infliximab. 11. The aqueous solution of claim 1, wherein the antibody protein is a fusion protein comprising an active protein domain fused to one or more immunoglobulin Fc fragments. 12. The aqueous solution of claim 11, wherein the antibody protein is etanercept, abatacept or belatacept. 13. The aqueous solution of claim 1, wherein the antibody protein is certolizumab pegol. 14. The aqueous solution of claim 1, wherein the antibody protein concentration is between about 25 mg/mL and about 300 mg/mL. 15. The aqueous solution of claim 1, wherein the antibody protein concentration is greater than 50 mg/mL. 16. The aqueous solution or method of claim 1, wherein the weight ratio (wt/wt) of antibody protein to the oligomer of ethyleneimine is at least 10. 17. The aqueous solution of claim 1, wherein the pI of the antibody protein is at least 7. 18. The aqueous solution of claim 17, wherein the pI of the antibody protein is in the range of 7 to 10. 19. A packaged pharmaceutical composition suitable for administration to a subject in need thereof, comprising the aqueous solution of claim 1. 20. The aqueous solution of claim 1, wherein the oligomer of ethyleneimine is triethylenetetramine. 21. The aqueous solution of claim 1, wherein the pH of the solution is in the range 5 to 7.5. 22. The aqueous solution of claim 10, wherein the pI of the antibody protein is in the range of 7 to 10. 23. The aqueous solution of claim 11, wherein the pI of the antibody protein is in the range of 7 to 10. 24. The aqueous solution of claim 1, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range consisting of 6 to 12. 25. The aqueous solution of claim 1, wherein the number of repeating units of ethyleneimine (n) is 4. 26. The aqueous solution of claim 1, wherein the number of repeating units of ethyleneimine (n) is 5. |
Details for Patent 10,532,098
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2040-01-24 |
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2040-01-24 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2040-01-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.